Clinical trials
Phase 1/2 Multiple Myeloma trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
56 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2006 | 2 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 6 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 7 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 56 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ascentage Pharma Group Inc. | 2 |
| Chinese PLA General Hospital | 2 |
| Oncotherapeutics | 2 |
| 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 1 |
| Asclepius Technology Company Group (Suzhou) Co., Ltd. | 1 |
| CARsgen Therapeutics Co., Ltd. | 1 |
| Celyad Oncology SA | 1 |
| Chongqing Precision Biotech Co., Ltd | 1 |
| Chonnam National University Hospital | 1 |
| Ciusss de L'Est de l'Île de Montréal | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Myeloma | 56 |
| Neoplasms, Plasma Cell | 8 |
| Lymphoma | 4 |
| Recurrence | 4 |
| Lymphoma, Non-Hodgkin | 3 |
| Blood Protein Disorders | 2 |
| Hematologic Diseases | 2 |
| Hematologic Neoplasms | 2 |
| Hodgkin Disease | 2 |
| Leukemia | 2 |
Trials
Showing 1 to 25 of 56. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.